RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: A treatment planning comparison study

Radiation Oncology

Volumn 4, Issue , 2009, Pages 34-

  Weber, Damien C ^a,d   Wang, Hui ^a   Cozzi, Luca ^b   Dipasquale, Giovanna ^a   Khan, Haleem G ^c   Ratib, Osman ^a,d   Rouzaud, Michel ^a   Vees, Hansjoerg ^a   Zaidi, Habib ^a   Miralbell, Raymond ^a,d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c Institut de Radiologie Jean Violette   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HISTOGRAM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PHOTON THERAPY; PROSTATE CANCER; PROTON THERAPY; RADIATION DOSE; RECTUM; TREATMENT PLANNING; URETHRA; VOLUMETRY;

EID: 70350117998     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-4-34     Document Type: Article

References (33)

1. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005, 63:1463-1468. 10.1016/j.ijrobp.2005.05.054, 16169683.
2. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostat cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003, 57:915-928.
3. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR, . Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008, 112:307. 10.1002/cncr.23161, 18050294.
4. Zagars GK, Pollack A, von Eschenbach AC. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995, 33:23-35.
5. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006, 36:73-92. 10.1053/j.semnuclmed.2005.09.002, 16356797.
6. Palma D, Vollans E, James K, Nakano S, Moiseenko V, Shaffer R, McKenzie M, Morris J, Otto K. Volumetric modulated arc therapy for delivery of prostate radiotherapy. Comparison with intensity modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72(4):996-1001.
7. Kjær-Kristoffersen F, Ohlhues L, Medin J, Korreman S. RapidArc volumetric modulated therapy planning for prostate cancer patients. Acta Oncol 2009, 48(2):227-32. 10.1080/02841860802266748, 18855157.
8. Cozzi L, Dinshaw KA, Shrivastava SK, Mahantshetty U, Engineer R, Deshpande DD, Jamema SV, Vanetti E, Clivio A, Nicolini G, Fogliata A. A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother Oncol 2008, 89:180-91. 10.1016/j.radonc.2008.06.013, 18692929.
9. Clivio A, Fogliata A, Franzetti-Pellanda A, Nicolini G, Vanetti E, Wyttenbach R, Cozzi L. Volumetric arc modulated radiotherapy for carcinoams of the anal canal. A treatment planning comparison with fixed field IMRT. Radiother Oncol 2009, 92(1):118-24. 10.1016/j.radonc.2008.12.020, 19181409.
10. Miralbell R, Vees H, Lozano J, Khan H, Mollà M, Hidalgo A, Linero D, Rouzaud M. Endorectal MRI assessment of local relapse after surgery for prostate cancer: A model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys 2007, 67:356-361.
11. Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Grégoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol 2003, 69:247-250. 10.1016/S0167-8140(03)00270-6, 14644483.
12. Vees H, Senthamizhchelvan S, Miralbell R, Weber DC, Ratib O, Zaidi H. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nuc Med Mol Imaging 2009, 36:182-193.
13. Steiner C, Vees H, Zaidi H, Wissmeyer M, Berrebi O, Kossovsky MP, Khan HG, Miralbell R, Ratib O, Buchegger F. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin 2009, 48:1-9. quiz N2-3.
14. Casanova N, Zilli T, Rouzaud M, Dipasquale G, Nouet P, Wang H, Escudé L, Mollà M, Linero D, Miralbell R. Sequential dose escalation study with two different hypofractionated IMRT techniques for localized prostate cancer: acute toxicity. Int J Radiat Oncol Biol Phys 2008, 72(1). S289 (abstract 2268).
15. Ulmer W, Pyyry J, Kaissl W. A 3D photon superposition/convolution algorithm and its foundation on results of Monte Carlo calculations. Phys Med Biol 2005, 50:1767-90. 10.1088/0031-9155/50/8/010, 15815095.
16. Chui C, LoSasso T, Spirou S. Dose calculation for photon beams with intensity modulation generated by dynamic jaw or multileaf collimations. Med Phys 1994, 21:1237-1244. 10.1118/1.597206, 7799865.
17. Ulmer W. Theoretical aspects of energy range relations, stopping power and energy straggling of protons. Radiat Phys and Chem 2007, 76:1089-1107.
18. Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997, 15:230-238.
19. Donnelly BJ, Saliken JC, Ernst DS, Weber B, Robinson JW, Brasher PM, Rose M, Rewcastle J. Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. Prostate Cancer Prostatic Dis 2005, 8:235-242. 10.1038/sj.pcan.4500811, 15983627.
20. Nguyen PL, Chen MH, D'Amico AV, Tempany CM, Steele GS, Albert M, Cormack RA, Carr-Locke DL, Bleday R, Suh WW. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 2007, 110:1485-1492. 10.1002/cncr.22934, 17701957.
21. Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, Kim HL, Lugg J, Childs SJ, Shuman B, Jayson MA, Shore ND, Moore Y, Zisman A, Lee JY, Ugarte R, Mynderse LA, Wilson TM, Sweat SD, Zincke H, Belldegrun AS. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 2003, 170:1126-1130. 10.1097/01.ju.0000087860.52991.a8, 14501706.
22. Sanderson KM, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol 2006, 176:2025-2031. discussion 2031-2022, 10.1016/j.juro.2006.07.075, 17070244.
23. Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M, Hsu IC. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007, 67:1106-1112.
24. Miles EF, Lee WR. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol 2008, 18:41-47. 10.1016/j.semradonc.2007.09.006, 18082587.
25. Wong GW, Palazzi-Churas KL, Jarrard DF, Paolone DR, Graf AK, Hedican SP, Wegenke JD, Ritter MA. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 2008, 70:449-455.
26. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997, 44:213-221. 10.1016/S0167-8140(97)00123-0, 9380819.
27. Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005, 23:826-831. 10.1200/JCO.2005.02.111, 15681527.
28. Huang WC, Kuroiwa K, Serio AM, Bianco FJ, Fine SW, Shayegan B, Scardino PT, Eastham JA. The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies. J Urol 2007, 177:1324-1329. 10.1016/j.juro.2006.11.069, 17382724.
29. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, Souvatzogluou M, Gildehaus FJ, Wester HJ, Dresel S. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007, 34:45-53. 10.1007/s00259-006-0190-7, 16932935.
30. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, Cservenyàk T, Hany TF. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:253-263. 10.1007/s00259-007-0552-9, 17926036.
31. Reske SN, Blumstein NM, Glatting G. [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008, 35:9-17. 10.1007/s00259-007-0530-2, 17828534.
32. Bortfeld T, Webb S. Single-arc IMRT?. Phys Med Biol 2009, 54:9-20.
33. Sylvester J, Grimm P, Blasco J, Meier R, Spiegel J, Heaney C, Cavanagh W. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States. Urology 2001, 58:65-70. 10.1016/S0090-4295(01)01244-4, 11502452.